Amalgamated Bank increased its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 5.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,796 shares of the medical technology company’s stock after acquiring an additional 729 shares during the quarter. Amalgamated Bank’s holdings in Hill-Rom were worth $1,163,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of HRC. Royal Bank of Canada boosted its stake in Hill-Rom by 38.9% during the second quarter. Royal Bank of Canada now owns 4,959 shares of the medical technology company’s stock worth $395,000 after acquiring an additional 1,390 shares in the last quarter. Aperio Group LLC boosted its stake in Hill-Rom by 8.1% during the third quarter. Aperio Group LLC now owns 23,219 shares of the medical technology company’s stock worth $1,718,000 after acquiring an additional 1,735 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in Hill-Rom during the third quarter worth $638,000. Stevens Capital Management LP boosted its stake in Hill-Rom by 11.4% during the third quarter. Stevens Capital Management LP now owns 13,370 shares of the medical technology company’s stock worth $989,000 after acquiring an additional 1,369 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Hill-Rom by 385.0% during the third quarter. American Century Companies Inc. now owns 535,229 shares of the medical technology company’s stock worth $39,607,000 after acquiring an additional 424,870 shares in the last quarter. 82.50% of the stock is currently owned by institutional investors and hedge funds.
HRC has been the topic of several research analyst reports. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research note on Thursday, November 16th. Bank of America reissued a “hold” rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Stifel Nicolaus reissued a “buy” rating and set a $92.00 target price on shares of Hill-Rom in a research note on Wednesday, November 29th. KeyCorp reissued a “buy” rating and set a $94.00 target price on shares of Hill-Rom in a research note on Thursday, December 21st. Finally, Morgan Stanley lowered shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Hill-Rom presently has a consensus rating of “Buy” and an average price target of $95.38.
Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, January 26th. The medical technology company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.13. Hill-Rom had a net margin of 4.02% and a return on equity of 7.66%. The firm had revenue of $669.70 million for the quarter, compared to analyst estimates of $670.00 million. During the same period last year, the firm earned $0.75 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. equities research analysts anticipate that Hill-Rom Holdings, Inc. will post 4.62 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 23rd will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.91%. This is a positive change from Hill-Rom’s previous quarterly dividend of $0.18. The ex-dividend date of this dividend is Thursday, March 22nd. Hill-Rom’s dividend payout ratio (DPR) is 35.29%.
In other news, CEO John J. Greisch sold 125,241 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the sale, the chief executive officer now owns 280,851 shares in the company, valued at $23,195,484.09. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total transaction of $82,990.00. Following the completion of the sale, the senior vice president now owns 1,066 shares of the company’s stock, valued at approximately $88,467.34. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by company insiders.
WARNING: “Hill-Rom Holdings, Inc. (HRC) Shares Bought by Amalgamated Bank” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/13/hill-rom-holdings-inc-hrc-shares-bought-by-amalgamated-bank.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.